TickerGuard
Buy Day today: Good (67) Broad market participation · no major macro event

Replimune Group Inc (REPL)

Healthcare Biotechnology
11.90 $
+6.3% vs. previous close
Closing price · As of: 3. Aug 2026

Replimune Group Inc (REPL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Revenue" came in at 0.0 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Income Statement REPL
Tick rows to compare them in a chart (up to 4) Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 LTM
0.0 0.0 0.0 4.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0
0.6 0.7 0.7 0.7 0.7 0.9 1.0 0.8 1.7 1.6 1.6
-0.6 -0.7 -0.7 3.4 -0.7 -0.9 -1.0 -0.8 -1.7 -1.6 -1.6
40 49 43 43 43 43 48 55 58 58 53 52 221
15 15 14 16 14 15 18 25 33 26 19 21 99
56 64 57 59 57 59 66 79 90 84 72 73 320
-56 -64 -57 -59 -57 -59 -66 -80 -90 -84 -72 -73 -320
1.7 1.5 1.6 2.0 2.0 2.0 2.0 2.0 2.0 0.5 2.0 4.4 8.9
-49 -60 -51 -55 -54 -53 -66 -75 -87 -83 -71 -73 -314
0.2 -0.2 0.5 -0.1 -0.4 -0.4 0.6 -0.7 -0.4 -0.3 -0.2
-50 -60 -51 -55 -54 -53 -66 -74 -87 -83 -71 -73 -314
-55 -63 -55 -55 -56 -58 -65 -72 -89 -82 -68 -75 -314

LTM = last twelve months (sum of the four most recent quarters).

Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?